Kidney Progenitor Exosomes

Overview

Parent Cell: Akira Kidney Progenitor Cells differentiated from UCT-WJ-MSCs | Nephroprotective and anti-inflammatory growth factors and miRNAs for kidney repair and regeneration

Related: Exosomes Overview • Kidney Progenitor Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Kidney Progenitor Exosomes are derived from kidney progenitor cells (KPCs) produced by stepwise directed differentiation of UCT-WJ-MSCs through intermediate mesoderm and metanephric mesenchyme stages. This recapitulates renal organogenesis, generating cells expressing the key renal progenitor transcription factors SIX2, PAX2, WT1, and LHX1. Podocalyxin (PODXL) expression confirms glomerular progenitor identity.

Kidney progenitor-derived exosomes are enriched with BMP-7 — a critical anti-fibrotic and tubulogenesis-promoting renal morphogen — and HGF, the primary tubular epithelial repair factor. The miR-200 family cargo suppresses epithelial-to-mesenchymal transition (EMT), a central driver of progressive renal fibrosis and tubular atrophy. This preparation addresses the core pathological mechanisms of acute kidney injury (AKI), chronic kidney disease (CKD), and diabetic nephropathy.^[1]

Mechanism of Action

Tubular Epithelial Repair (HGF/EGF Pathway): HGF is the dominant tubular regeneration factor, activating c-Met on proximal tubular epithelial cells to drive proliferation, migration, and restoration of tubular architecture following AKI. EGF provides complementary mitogenic support through EGFR. These growth factors collectively re-establish the proximal tubule epithelium that is most vulnerable to ischemic and nephrotoxic injury.

Anti-Fibrotic Signaling (BMP-7 & miR-200): BMP-7 is a potent endogenous anti-fibrotic morphogen in the kidney, counteracting TGF-β1-driven tubular EMT in human renal proximal tubular epithelial cells^[2] and interstitial fibrosis. The miR-200 family (miR-200a/b/c, miR-141, miR-429) directly suppresses ZEB1 and ZEB2 — the transcription factors that drive EMT — maintaining tubular epithelial phenotype and preventing fibroblast transition. Together these mechanisms address the fibrotic remodeling that underlies progressive CKD.

Glomerular Protection: VEGF maintains podocyte integrity and glomerular endothelial fenestration — essential for normal filtration barrier function, consistent with the regulation of angiogenic factors observed in angiotensin-II-driven tubulointerstitial injury models.^[3] miR-30a is a podocyte-specific miRNA that suppresses apoptosis and maintains podocyte foot process structure — TGF-β-induced miR-30d downregulation drives podocyte injury via Smad2/3 and HDAC3-associated transcriptional repression,^[4] and protecting against this miR-30 downregulation preserves podocytes from TGF-β-induced injury.^[5] WT1 and PODXL-associated cargo support the maintenance of the glomerular filtration apparatus, relevant to diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), and membranous nephropathy research.

Renal Inflammation Resolution: miR-146a and miR-21 suppress NF-κB in renal tubular cells and infiltrating macrophages, reducing NLRP3 activation and the IL-1β/TNF-α cascade driving nephron loss (consistent with miR-146a's broader anti-inflammatory, NLRP3-suppressing role in metabolic disease^[6] and macrophage inflammasome activation^[7]). IL-10 from the secretome promotes M2 macrophage polarization in the renal interstitium. Ang-1 stabilizes peritubular capillaries, preventing the microvascular rarefaction that accelerates CKD progression.^[8] miR-21 separately protects tubular epithelial cells from apoptosis during acute ischemic/inflammatory kidney injury.^[9]

Key Molecular Cargo

Potential Applications

• Acute Kidney Injury: HGF/EGF tubular repair; miR-146a inflammation resolution; VEGF peritubular capillary maintenance.
• Chronic Kidney Disease: BMP-7 and miR-200 anti-fibrotic activity; glomerular protection via miR-30a and VEGF.
• Diabetic Nephropathy: Podocyte protection via miR-30a/VEGF; anti-inflammatory renal macrophage modulation.
• FSGS Research: Podocyte survival signaling; miR-30 family foot process maintenance.
• Renal Fibrosis: BMP-7 counteracts TGF-β1; miR-200 suppresses EMT; Ang-1 supports peritubular capillary preservation.
• IgA Nephropathy: Extrapolated from anti-inflammatory MSC-exosome mechanism data and analogous glomerular-disease models (e.g., diabetic kidney disease).
• Contrast-Induced Nephropathy: Tubular anti-apoptotic HGF/IGF-1 cargo; vasoprotective VEGF/Ang-1.
• Renal Transplant Research: Anti-inflammatory and anti-fibrotic cargo mechanistically relevant to delayed graft function and chronic allograft nephropathy research, consistent with the increase in proliferating renal progenitor cells observed in acute tubular necrosis underlying delayed graft function.^[10]

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

The evidence base for this preparation is preclinical and mechanistic rather than product-specific clinical trial data, though MSC-derived extracellular vesicles for renal repair^[8] and MSC therapies more broadly^[1] have reached clinical translation in nephrology. A systematic review and meta-analysis of animal models confirms MSC-derived extracellular vesicles reduce injury in ischemia/reperfusion-induced AKI,^[11] with a porcine IRI model showing direct amelioration of acute kidney injury following exosome administration,^[12] and a 2025 meta-analysis confirming therapeutic benefit of MSC exosomes in chronic kidney disease.^[13] See the Akira Kidney Progenitor Cells guide for whole-cell trial data from the same lineage.